Bile duct cancer

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
2 Unique sponsors
5 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Kinase inhibitor 2 substances
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Merck Sharp & Dohme LLC Commercial
    BELZUTIFAN; LENVATINIB
    2025-524160-38-00 10 countries 2026 n=37
    Recruiting

Phase II

1 trial
  • Bayer Consumer Care AG Commercial
    3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; SEVABERTINIB
    2024-517419-62-00 4 countries 2025 n=37
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bayer Consumer Care AG Commercial 1 Phase II 1
Merck Sharp & Dohme LLC Commercial 1 Phase III 1
New trials by year
2025
1
2026
1
← All indication landscapes